Rapid, highly sensitive diagnostic provides patient HIV tropism status needed to initiate therapy with Pfizer's recently approved Selzentry(TM)
(Maraviroc), CCR5 antagonist.
MALIBU, Calif., Sept. 17 /PRNewswire/ -- Pathway Diagnostics announces nationwide availability of SensiTrop(TM), its proprietary molecular heteroduplex tracking assay (HTA) for determining the co-receptor tropism status of HIV infected patients. Pathway performs the SensiTrop(TM) assay in its CLIA approved laboratory on samples received from Mayo Medical Laboratories and other soon-to-be named national laboratories.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070917/LAM073LOGO)
Recently Pfizer Inc. and the FDA announced the approval of Selzentry(TM) (Maraviroc), the first in a novel class of anti-retroviral drugs based on blocking the CCR5 co-receptor of HIV. Selzentry, in combination with other antiretroviral agents, is indicated for treatment-experienced adult HIV patients with only CCR5-tropic HIV-1 detectable who have evidence of viral replication, and HIV-1 strains resistant to multiple anti-retroviral agents. The FDA label states that when initiating therapy, tropism testing and treatment history should guide the use of Selzentry.
"Pathway is pleased to introduce this second generation diagnostic HIV tropism assay nationwide, providing clinicians a fast, sensitive and economical testing alternative to the currently available biological HIV tropism assay," said Walter Narajowski, Pathway Diagnostics President and CEO. "This timely introduction of SensiTrop is a perfect example of Pathway's strategy to license proprietary biomarkers, develop them, and rapidly commercialize them with diagnostic partners."
SensiTrop(TM) is a molecular based assay designed and demonstrated to
be highly-sensitive in detecting CXCR4-tropic HIV in patient samples that
'/>"/>
| SOURCE Pathway Diagnostics Corporation Copyright©2007 PR Newswire. All rights reserved |